Understanding artemisinin-resistant malaria: What a difference a year makes

Current Opinion in Infectious Diseases

Volumn 28, Issue 5, 2015, Pages 417-425

  Fairhurst, Rick M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

artemisinin; malaria; parasite kelch protein; Plasmodium falciparum; resistance

Indexed keywords

ARTEMISININ; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ADAPTIVE IMMUNITY; CHROMOSOME 13; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MALARIA FALCIPARUM; MONOTHERAPY; PARASITE CLEARANCE; PARASITE SURVIVAL; POPULATION GENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; DRUG EFFECTS; DRUG RESISTANCE; GENE; GENETICS; PARASITOLOGY; PHYSIOLOGY; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; GENES, PROTOZOAN; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 84945129853     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000199     Document Type: Review

References (50)

1. Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005; 366: 717-725.
2. Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010; 376: 1647-1657.
3. Dondorp AM, Fairhurst RM, Slutsker L, et al. The threat of artemisinin-resistant malaria. N Engl J Med. 2011; 365: 1073-1075.
4. Chotivanich K, Udomsangpetch R, Dondorp A, et al. The mechanisms of parasite clearance after antimalarial treatment of Plasmodium falciparum malaria. J Infect Dis. 2000; 182: 629-633.
5. Buffet PA, Milon G, Brousse V, et al. Ex vivo perfusion of human spleens maintains clearing and processing functions. Blood. 2006; 107: 3745-3752.
6. White NJ. The parasite clearance curve. Malar J. 2011; 10: 278-285.
7. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J. 2011; 10: 339-352.
8. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361: 455-467.
9. Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis. 2012; 12: 851-858.
10. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014; 371: 411-423.
11. Thriemer K, Hong NV, Rosanas-Urgell A, et al. Delayed parasite clearance after treatment with dihydroartemisinin-piperaquine in Plasmodium falciparum malaria patients in central Vietnam. Antimicrob Agents Chemother. 2014; 58: 7049-7055.
12. Hien TT, Thuy-Nhien NT, Phu NH, et al. In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J. 2012; 11: 355-366.
13. Phyo AP, Nkhoma S, Stepniewska K, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012; 379: 1960-1966.
14. Kyaw MP, Nyunt MH, Chit K, et al. Reduced susceptibility of Plasmodium falciparum to artesunate in southern Myanmar. PLoS One. 2013; 8: e57689-e57699.
15. Huang F, Takala-Harrison S, Jacob CG, et al. A single mutation in K13 predominates in Southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis 2015. [Epub ahead of print
16. Lopera-Mesa TM, Doumbia S, Konate D, et al. Impact of red blood cell variants on childhood malaria in Mali: a prospective cohort study. Lancet Haematol. 2015; 2: e140-e149.
17. Lopera-Mesa TM, Doumbia S, Chiang S, et al. Plasmodium falciparum clearance rates in response to artesunate in Malian children with malaria: effect of acquired immunity. J Infect Dis. 2013; 207: 1655-1663.
18. Ndour PA, Lopera-Mesa TM, Diakite SA, et al. Plasmodium falciparum clearance is rapid and pitting independent in immune Malian children treated with artesunate for malaria. J Infect Dis. 2015; 211: 290-297.
19. Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis. 2013; 13: 1043-1049.
20. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisininresistant Plasmodium falciparum malaria. Nature. 2014; 505: 50-55.
21. Amaratunga C, Witkowski B, Dek D, et al. Plasmodium falciparum founder populations in western Cambodia have reduced artemisinin sensitivity in vitro. Antimicrob Agents Chemother. 2014; 58: 4935-4937.
22. Straimer J, Gnadig NF, Witkowski B, et al. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates. Science. 2015; 347: 428-431.
23. Takala-Harrison S, Clark TG, Jacob CG, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A. 2013; 110: 240-245.
24. Cheeseman IH, Miller BA, Nair S, et al. A major genome region underlying artemisinin resistance in malaria. Science. 2012; 336: 79-82.
25. Nyunt MH, Hlaing T, Oo HW, et al. Molecular assessment of artemisinin resistance markers, polymorphisms in the k13 propeller, and a multidrugresistance gene in the eastern and western border areas of Myanmar. Clin Infect Dis. 2015; 60: 1208-1215.
26. Takala-Harrison S, Jacob CG, Arze C, et al. Independent emergence of artemisinin resistance mutations among Plasmodium falciparum in Southeast Asia. J Infect Dis. 2015; 211: 670-679.
27. Bosman P, Stassijns J, Nackers F, et al. Plasmodium prevalence and artemisinin-resistant falciparum malaria in Preah Vihear Province, Cambodia: a cross-sectional population-based study. Malar J. 2014; 13: 394-403.
28. Talundzic E,Okoth SA,Congpuong K, et al.Selection and spread of artemisininresistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog. 2015; 11: e1004789-e1004803.
29. Tun KM, Imwong M, Lwin KM, et al. Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infect Dis. 2015; 15: 415-421.
30. Feng J, Zhou D, Lin Y, et al. Amplification of pfmdr1, pfcrt, pvmdr1, and K13 propeller polymorphisms associated with Plasmodium falciparum and Plasmodium vivax isolates from the China-Myanmar border. Antimicrob Agents Chemother. 2015; 59: 2554-2559.
31. Wang Z, Shrestha S, Li X, et al. Prevalence of K13-propeller polymorphisms in Plasmodium falciparum from China-Myanmar border in 2007-2012. Malar J. 2015; 14: 168-174.
32. Mohon AN, Alam MS, BayihAG, et al. Mutations in Plasmodium falciparumK13 propeller gene from Bangladesh (2009-2013). Malar J. 2014; 13: 431-437.
33. Leang R, Taylor WR, Bouth DM, et al. Evidence of falciparum malaria multidrug resistance to artemisinin and piperaquine in western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015; 59: 4719-4726.
34. Spring MD, Lin JT, Manning JE, et al. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study. Lancet Infect Dis. 2015; 15: 683-691.
35. Taylor SM, Parobek CM, DeConti DK, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015; 211: 680-688.
36. Kamau E, Campino S, Amenga-Etego L, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis. 2015; 211: 1352-1355.
37. Escobar C, Pateira C, Lobo E, et al. Polymorphisms in Plasmodium falciparum K13-propeller in Angola and Mozambique after the introduction of the ACTs. PLoS One. 2015; 10: e0119215-e0119221.
38. Ouattara A, Kone A, Adams M, et al. Polymorphisms in the K13-propeller gene in artemisinin-susceptible Plasmodium falciparum parasites from Bougoula-Hameau and Bandiagara, Mali. Am J Trop Med Hyg. 2015; 92: 1202-1206.
39. Hawkes M, Conroy AL, Opoka RO, et al. Slow clearance of Plasmodium falciparum in severe pediatric malaria, Uganda, 2011-2013. Emerg Infect Dis. 2015; 21: 1237-1239.
40. Conrad MD, Bigira V, Kapisi J, et al. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One. 2014; 9: e105690-e105696.
41. Miotto O, Almagro-Garcia J, Manske M, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013; 45: 648-655.
42. Miotto O, Amato R, Ashley EA, et al. Genetic architecture of artemisininresistant Plasmodium falciparum. Nat Genet. 2015; 47: 226-234.
43. Ghorbal M, Gorman M, Macpherson CR, et al. Genome editing in the human malaria parasite Plasmodium falciparum using the CRISPR-Cas9 system. Nat Biotechnol. 2014; 32: 819-821.
44. Mok S, Ashley EA, Ferreira PE, et al. Drug resistance. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science. 2015; 347: 431-435.
45. Dogovski C, Xie SC, Burgio G, et al. Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance. PLoS Biol. 2015; 13: e1002132.
46. Hott A, Casandra D, Sparks KN, et al. Artemisinin-resistant Plasmodium falciparum parasites exhibit altered patterns of development in infected erythrocytes. Antimicrob Agents Chemother. 2015; 59: 3156-3167.
47. Mbengue A, Bhattacharjee S, Pandharkar T, et al. A molecular mechanism of artemisinin resistance in Plasmodium falciparum malaria. Nature. 2015; 520: 683-687.
48. Leang R, Barrette A, Bouth DM, et al. Efficacy of dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax in Cambodia, 2008 to 2010. Antimicrob Agents Chemother. 2013; 57: 818-826.
49. Chaorattanakawee S, Saunders DL, Sea D, et al. Ex vivo drug susceptibility and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia in 2008-2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother. 2015; 59: 4631-4643.
50. Lim P, Dek D, Try V, et al. Decreasing pfmdr1 copy number suggests that Plasmodium falciparum in Western Cambodia is regaining in vitro susceptibility to mefloquine. Antimicrob Agents Chemother. 2015; 59: 2934-2937.